Fast Track
In development for hemodialysis patients
09-11-2008 |
10:13 hs.
09-05-2008 |
12:54 hs.
Dirucotide (MBP8298)
09-04-2008 |
11:26 hs.
Canada´s BioMS Medical Corp announced its lead experimental drug for the treatment of multiple sclerosis dirucotide (MBP8298) was granted fast-track status by the U.S. Food and Drug Administration.
OGX-011 (custirsen sodium)
08-26-2008 |
10:25 hs.
Treatment of symptomatic neurogenic orthostatic hypotension
08-26-2008 |
09:50 hs.
06-03-2008 |
12:00 hs.
Biotech firm Lexicon Pharmaceuticals said the FDA granted Fast Track Status to its experimental LX1032, an oral small molecule drug candidate designed for the management of gastrointestinal symptoms associated with carcinoid syndrome. Lexicon will initiate a multi-dose Phase 1b trial of LX1032 in June 2008
Intestinal gel for treatment of motor fluctuations associated with Par
02-19-2008 |
12:46 hs.
Belgian drugmaker Solvay said the FDA has granted Fast Track designation to the development program for Duodopa intestinal gel for long-term treatment of motor fluctuations associated with advanced Parkinson’s disease
